14 rue de la République
Suresnes 92150
France
https://pharnext.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 23
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Daniel E. Cohen M.D., Ph.D. | Director | 319,3k | S.O. | 1953 |
Mr. Hugo Brugiere M.Sc. | CEO & Chairman | S.O. | S.O. | S.O. |
Mr. Ilya Chumakov D-Sc, Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Director | S.O. | S.O. | S.O. |
Mr. Vincent Serra Ph.D. | COO & Chief Scientific Officer | S.O. | S.O. | 1970 |
Mr. Abhijit Pangu | Head of Regulatory Affairs | S.O. | S.O. | S.O. |
Mr. Raj Thota M.Sc. | Chief Manufacturing Officer & Head of CMC | S.O. | S.O. | S.O. |
Mr. Scott Johnson B.Sc. | VP & Head of Quality | S.O. | S.O. | S.O. |
Mr. Gilbert Wagener M.D., Ph.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
L’ISS Governance QualityScore de Pharnext S.C.A. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..